Navigation Links
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Date:9/12/2008

y dialing (706) 645-9291; the PIN access number is 64328875.

About Angina

There are currently 48-50 million angina prescriptions written annually in the largest five EU member countries (UK, Germany, France, Spain and Italy). Chronic angina is a serious and debilitating heart condition, usually associated with coronary artery disease and marked by repeated and sometimes unpredictable attacks of chest pain.

About Menarini

The Menarini Group is one of the largest privately owned pharmaceutical companies, and is headquartered in Florence, Italy. Menarini employs approximately 12,500 people, with a strong presence throughout Europe, CIS, Africa and in South and Central America. The company has expertise in successfully developing and commercializing in-licensed drug products from major companies in a broad range of therapeutic areas. The Group's total revenue exceeds euro 2.5 billion.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics to Host Investor Day in Milan, Italy on Friday, October 3, 2008
2. Halozyme Therapeutics to Present at Upcoming Investor Conferences
3. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
4. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
7. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
11. Cell Therapeutics, Inc. Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 1, 2015  Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology, presented data on ... the 2015 Experimental Biology conference in ... represents an ideal extension of Organovo,s capabilities to ... useful in pharmaceutical research," said Keith Murphy ...
(Date:4/1/2015)... April 1, 2015  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... held full service global investment bank specializing in ... industry note featuring Spherix. The report, ... Senior Analyst at Chardan, was published on March ...
(Date:4/1/2015)... , April 1, 2015 ... developing novel biological drugs to treat cancer, viral ... announce the appointment of Christina Coughlin ... responsible for providing medical and regulatory leadership to ... Dr. Coughlin has extensive experience in ...
(Date:3/31/2015)... 2015 Materials in Society Lecture ... June 30 2015   Elsevier , a ... services and publishing home of Materials Today , announced ... Materials in Society  Lecture Series . ... th International Conference on Materials for Advanced Technologies (ICMAT) ...
Breaking Biology Technology:Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 2Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 3Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 4Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3
... -- 3SBio Inc.,(Nasdaq: SSRX ), a ... marketing biopharmaceutical products primarily,in China, today announced that ... Financial,Officer, effective February 1, 2009. Since joining 3SBio ... the financial advisor for the company, providing advice,on ...
... Ireland, February 9, Shire plc (LSE: SHP, NASDAQ: ... Notice letters from Barr Laboratories, Inc.,("Barr) and Mylan, Inc. ... each case of the filing of an Abbreviated New ... and 1gm FOSRENOL(R),(lanthanum carbonate). , ...
... Feb. 9 , , ... new Progen board , Call by ... Significant funding shortfall identified in the Progen merger ... Requisition , Late last week Progen Pharmaceuticals Limited (ASX: PGL) responded ...
Cached Biology Technology:3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer 2Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan 2Cytopia and Other Progen Shareholders Maintain Call for Meeting 2Cytopia and Other Progen Shareholders Maintain Call for Meeting 3Cytopia and Other Progen Shareholders Maintain Call for Meeting 4
(Date:4/1/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces the second shipment of ... to early access pre-order customers. Feedback ... outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop & ... at all outlets and very easy to use. Several ...
(Date:4/1/2015)... --  Medisafe ™, the leading global medication management platform ... and Android smartphones and tablets, announces today ... to allow patients to track and correlate their adherence ... will be able to visualize in real-time how taking ... as glucose levels and blood pressure. "Patients ...
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... to any process by which a cell converts one ... of signal transduction involve ordered sequences of biochemical reactions ... and activated by second messengers, resulting in a signal ... the order of milliseconds in the case of ion ...
... found the dose of DHA (docosahexaenoic acid) that is "just ... research report appearing in the September 2009 print issue of ... show that a 200 mg dose of DHA per day ... problems, such as those related to aging, atherosclerosis, and diabetes. ...
... Travelers to the neotropicsthe tropical lands of the Americasmight ... insects flittering over sunny puddles or among dense forest ... are moths that have reinvented themselves as butterflies, converging ... hairy relatives. Now, a new revision of the taxonomic ...
Cached Biology News:Moths cloaked in color 2Moths cloaked in color 3Moths cloaked in color 4
... Membrane Proteins ,Contains sufficient components to ... 2-D gel analysis , ,Includes:, , ... , (contains sufficient reagents for extracting ... weight of 10 mg each) Kit ...
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
... A sensitive and high speed homogeneous assay ... activity and for screening of inhibitors in ... is based on a fluorescence superquenching technology ... label. The universal platform provides flexibility for ...
... The HDA-GT12 Genetic Analyzer is ... multiple applications in one instrument platform. It ... in one step, thus significantly improving the ... to high-throughput laboratories . Benefits of ...
Biology Products: